Portal de Periódicos da CAPES

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials

2021; Elsevier BV; Volume: 22; Issue: 8 Linguagem: Inglês

10.1016/s1470-2045(21)00288-6

1474-5488

Rosie Bradley, Jeremy Braybrooke, Richard J. Gray, Robert K. Hills, Zulian Liu, Richárd Pető, Lucy Davies, David Dodwell, Paul McGale, Hongchao Pan, Carolyn Taylor, Stewart Anderson, Richard D. Gelber, Luca Gianni, William Jacot, Heikki Joensuu, Alvaro Moreno‐Aspitia, Martine Piccart, Michael F. Press, Edward H. Romond, Dennis J. Slamon, Vera J. Suman, Richard Berry, Clare Boddington, Mike Clarke, Christina Davies, Fran Duane, Vaughan Evans, Jo Gay, Lucy Gettins, Jon Godwin, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, Yaochen Wang, John Crown, Evandro de Azambuja, Suzette Delaloge, Helena Fung, Charles E. Geyer, M. Spielmann, Pinuccia Valagussa, Kathy S. Albain, Stewart Anderson, R. Arriagada, Thomas John, Elizabeth Bergsten-Nordström, Judith M. Bliss, Étienne Brain, Lisa B. Carey, Robert E. Coleman, Jack Cuzick, Nancy E. Davidson, Lucia Del Mastro, Angelo Di Leo, James J. Dignam, Mitch Dowsett, Bent Ejlertsen, Prudence A. Francis, Michael Gnant, Matthew Bidwell Goetz, Pam Goodwin, Pat Halpin-Murphy, Daniel Hayes, Catherine Hill, Reshma Jagsi, Wolfgang Janni, Sibylle Loibl, Eleftherios P. Mamounas, Miguel Martín, Hirofumi Mukai, Valentina Nekljudova, Larry Norton, Yasuo Ohashi, Lori J. Pierce, Philip Poortmans, Vinod Raina, Daniel Rea, Meredith M. Regan, J.F.R. Robertson, Emiel J. Rutgers, Tanja Španič, Joseph A. Sparano, Guenther G. Steger, Gong Tang, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Xiang Wang, Timothy J. Whelan, Nicholas Wilcken, Norman Wolmark, David Cameron, Jonas Bergh, Kathleen I. Pritchard, Sandra M. Swain,

Breast Cancer Treatment Studies

Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer reduces the risk of recurrence and death, but is associated with cardiac toxicity. We investigated the long-term benefits and risks of adjuvant trastuzumab on breast cancer recurrence and cause-specific mortality.